Colospan has attained CE marking for the CG-100 Intraluminal Bypass device as well as ISO 13485:2016 certification.
With strong IP, Colospan has registered patents in the United States, China and Japan.
It has completed entire verification and validation activities including an animal study, as well as a prospective multi-center trial with 60 patients aimed to evaluate safety, tolerability and performance of the CG-100 device. The study results show that the technical application of the CG-100 device is safe and feasible and meets the device performance.
Colospan enjoys solid financial backing from leading VCs from Israel, Europe and China, including Triventures, CBI, VLVJ, Anatomy, Docor, Virtus Inspire and the Alfred Mann Institute of Technology, part of the Technion Institute of Technology.